Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibuprofen + oxycodone is a combination analgesic regimen consisting of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the semi-synthetic opioid agonist oxycodone. This combination is utilized for the management of acute pain, particularly in emergency department settings for conditions such as ureteral calculi (kidney stones). Ibuprofen provides anti-inflammatory and analgesic effects by non-selectively inhibiting cyclooxygenase enzymes (COX-1 and COX-2), which reduces the synthesis of prostaglandins that mediate inflammation and pain. Oxycodone acts primarily as an agonist at mu-opioid receptors in the central nervous system, modulating the perception of and emotional response to pain. In a clinical trial sponsored by MaineHealth (NCT00311610), this combination served as the standard therapy control arm to evaluate the efficacy of tamsulosin in facilitating the passage of lower ureteral stones.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + oxycodone.